In Vivo is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Digital And Connected Care Are Pushing On An Open Door – But Is Medtech Ready?

Executive Summary

Digital health care will one day simply be "health care" in the same way that genomic medicine will simply become "medicine." But between then and now, there is much distance to cover – a lot of it in the minds of stakeholders who, maybe reluctantly, see it as a risky strategy. But the emerging consensus is that it represents opportunity.

You may also be interested in...



Medtechs Ready To Take Creative Approach To Deal-Making With An Eye On Start-Ups

Ground-breaking M&A deals were largely absent from medtech industry schedules in 2018 – Boston’s BTG deal aside – but that does not mean consolidation of the medtech industry is slowing down. M&A deal numbers have been steady of late, even if aggregate deal value has declined in recent years. Digital transformation is a catalyst for a growing number of sector-transforming transactions.

How The EHR And New Data Streams Are Influencing Clinical Practice

A plethora of clinical studies are showing that new types of data, often captured in the EHR, can help improve the correlation between treatments and outcomes and favorably affect patient care as well as enhance drug development.

World In Motion – The Shape Of The New Health Care Technology Ecosystem In 2022

The health products industry, methods of care delivery and even the public's expectations for improved tools to prevent, monitor and treat disease have transformed dramatically in the past five years. The changes anticipated over a similar period ahead are potentially even more marked, with business continuity impacts for medtech and pharma concerns, according to Deloitte LLP experts who were on the circuit at health care industry events in Germany and the UK this spring.

Related Content

Topics

Related Companies

Latest Headlines
See All
UsernamePublicRestriction

Register

IV005305

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel